Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys

References

• Boersma MG, van der Woude H, Bogaards J, et al. (2002). Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 15:662–70
   PubMed Web of Science ®Google Scholar
• Cayen MN, Kraml M, Ferdinandi ES, et al. (1981). The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab Rev 12:339–62
   PubMed Web of Science ®Google Scholar
• Chiou WL, Jeong HY, Chung SM, Wu TC. (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17:135–40
   PubMed Web of Science ®Google Scholar
• Court MH. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104–16
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Deguchi T, Watanabe N, Kurihara A, et al. (2011). Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos 39:820–9
   PubMed Web of Science ®Google Scholar
• FDA Drug Approval Package, Tasmar (Tolcapone) Tablets, Application No.20697, 1 Jan 1998, Pharmacology Reviews: 136, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20697_Tasmar_pharmr_P3.pdf [last accessed Nov 2010]
   Google Scholar
• Fisher MB, Labissiere G. (2007). The role of the intestine in drug metabolism and pharmacokinetics: an industry perspective. Curr Drug Metab 8:694–9
   PubMed Web of Science ®Google Scholar
• Furukawa T, Nakamori F, Tetsuka K, et al. (2012a). Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Drug Metab Pharmacokinet 27:171–80
   PubMed Web of Science ®Google Scholar
• Furukawa T, Yamano K, Naritomi Y, et al. (2012b). Method for predicting human intestinal first-pass metabolism of UGT substrate compounds. Xenobiotica 42:980–8
   PubMed Web of Science ®Google Scholar
• Ghosal A, Hapangama N, Yuan Y, et al. (2004). Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314–20
   PubMed Web of Science ®Google Scholar
• Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825–35
   PubMed Web of Science ®Google Scholar
• Haller S, Schuler F, Lazic SE, et al. (2012). Expression profiles of metabolic enzymes and drug transporters in the liver and along the intestine of beagle dogs. Drug Metab Dispos 40:1603–10
   PubMed Web of Science ®Google Scholar
• Kadono K, Akabane T, Tabata K, et al. (2010). Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230–7
   PubMed Web of Science ®Google Scholar
• Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700
   PubMed Web of Science ®Google Scholar
• Kilford PJ, Stringer R, Sohal B, et al. (2009). Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82–9
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto T, Chiba K, et al. (1998). Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26:818–21
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. (2011). In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev 43:476–98
   PubMed Web of Science ®Google Scholar
• Kosaka K, Sakai N, Endo Y, et al. (2011). Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab Dispos 39:1495–502
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467–94
   PubMed Web of Science ®Google Scholar
• Lindstrom TD, Whitaker NG, Whitaker GW. (1984). Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14:841–7
   PubMed Web of Science ®Google Scholar
• Madani S, Paine MF, Lewis L, et al. (1999). Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 16:1199–205
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. (2007). Contribution of UDP-glucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur J Clin Pharmacol 63:289–96
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94
   PubMed Web of Science ®Google Scholar
• Nakamori F, Naritomi Y, Furutani M, et al. (2011). Correlation of intrinsic in vitro and in vivo clearance for drugs metabolized by hepatic UDP-glucuronosyltransferases in rats. Drug Metab Pharmacokinet 26:465–73
   PubMed Web of Science ®Google Scholar
• Nakamori F, Naritomi Y, Hosoya K, et al. (2012). Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. Drug Metab Dispos 40:1771–7
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Terashita S, Kimura S, et al. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–24
   PubMed Web of Science ®Google Scholar
• Nishimura M, Koeda A, Morikawa H, et al. (2009). Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet 24:139–44
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Sato K, Yabuki M, Komuro S. (2011). Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26:592–601
   PubMed Web of Science ®Google Scholar
• Ohno S, Nakajin S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32–40
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan (2007). Review Report for Zetia (Ezetimebe) tablets:16, Available from: http://www.info.pmda.go.jp/shinyaku/P200700023/170050000_21900AMY00021000_A100_2.pdf [last accessed Apr 2013]
   Google Scholar
• Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, et al. (1991). Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm 19:647–65
   PubMedGoogle Scholar
• Priymenko N, Ferre JP, Rascol A, et al. (1993). Migrating motor complex of the intestine and absorption of a biliary excreted drug in the dog. J Pharmacol Exp Ther 267:1161–7
   PubMedGoogle Scholar
• Ritter JK. (2007). Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert. Opin. Drug Metab Toxicol 3:93–107
   PubMed Web of Science ®Google Scholar
• Rouguieg K, Picard N, Sauvage FL, et al. (2010). Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40–5
   PubMed Web of Science ®Google Scholar
• Rowland A, Gaganis P, Elliot DJ, et al. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro--in vivo extrapolation. J Pharmacol Exp Ther 321:137–47
   PubMed Web of Science ®Google Scholar
• Rowland A, Knights KM, Mackenzie PI, Miners JO. (2008). The “albumin effect” and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056–62
   PubMed Web of Science ®Google Scholar
• Sabolovic N, Heydel JM, Li X, et al. (2004). Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 1675:120–9
   PubMed Web of Science ®Google Scholar
• Sawada Y. (1985). Animal scale up. In: Hanano M, Umemura K, eds. Applied pharmacokinetics – theory and experiments. Tokyo: Soft Science, Inc., 477
   Google Scholar
• Shelby MK, Cherrington NJ, Vansell NR, Klaassen CD. (2003). Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326–33
   PubMed Web of Science ®Google Scholar
• Soars MG, Smith DJ, Riley RJ, Burchell B. (2001). Cloning and characterization of a canine UDP-glucuronosyltransferase. Arch Biochem Biophys 391:218–24
   PubMedGoogle Scholar
• Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449–56
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. (1981). A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–85
   PubMedGoogle Scholar
• Yoon IS, Choi MK, Kim JS, et al. (2011). Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243–51
   PubMed Web of Science ®Google Scholar